Table 1 Clinical parameters of the ICC patients
Parameters | Training cohort (n = 109) | Validation cohort (n = 47) | P-value |
|---|---|---|---|
Sex | Â | Â | 0.856 |
Male | 62(56.88) | 26(55.32) | Â |
Female | 47(43.12) | 21(44.68) | Â |
Age | Â | Â | 0.526 |
≤ 60 | 73(66.97) | 29(61.70) |  |
> 60 | 36(33.03) | 18(38.30) |  |
Tumor size (cm) | Â | Â | 0.662 |
≤ 5 | 31(28.44) | 15(31.91) |  |
> 5 | 78(71.56) | 32(68.09) |  |
Clinical N stage | Â | Â | 0.140 |
N0 | 51(46.79) | 16(34.04) | Â |
N1 | 58(53.21) | 31(65.96) | Â |
HBV infection | Â | Â | 0.042 |
Negative | 65(59.63) | 36(76.60) | Â |
Positive | 44(40.37) | 11(23.40) | Â |
Clonorchis sinensis infestation | Â | 0.413 | |
Negative | 79(72.48) | 31(65.96) | Â |
Positive | 30(27.52) | 16(34.04) | Â |
Hepatolithiasis | Â | Â | 0.389 |
Negative | 98(89.91) | 40(85.11) | Â |
Positive | 11(10.09) | 7(14.89) | Â |
AFP (ng/ml) | Â | Â | 0.802 |
≤ 20 | 101(92.66) | 43(91.49) |  |
> 20 | 8(7.34) | 4(8.51) |  |
CA199 (U/ml) | Â | Â | 0.133 |
≤ 37 | 56(51.38) | 18(38.30) |  |
> 37 | 53(48.62) | 29(61.70) |  |
CEA (ng/ml) | Â | Â | 0.195 |
≤ 5 | 70(64.22) | 25(53.19) |  |
> 5 | 39(35.78) | 22(46.81) |  |
LN metastasis | Â | Â | 0.064 |
No | 57(52.29) | 17(36.17) | Â |
Yes | 52(47.71) | 30(63.83) | Â |
NLR | Â | Â | 0.067 |
≤ 2.35 | 42(38.53) | 11(23.40) |  |
> 2.35 | 67(61.47) | 36(76.60) |  |
PLR | Â | Â | 0.528 |
≤ 214.59 | 84(77.06) | 34(72.34) |  |
> 214.59 | 25(22.94) | 13(27.66) |  |
SII | Â | Â | 0.089 |
≤ 490.34 | 30(27.52) | 7(14.89) |  |
> 490.34 | 79(72.48) | 40(85.11) |  |
PNI | Â | Â | 0.044 |
≤ 95.69 | 85(77.98) | 43(91.49) |  |
> 95.69 | 24(22.02) | 4(8.51) |  |
LMR | Â | Â | 0.137 |
≤ 2.24 | 33(30.28) | 20(42.55) |  |
> 2.24 | 76(69.72) | 27(57.45) |  |